Targeting Cognition in Bipolar Disorder With Pramipexole
Status:
Completed
Trial end date:
2018-07-26
Target enrollment:
Participant gender:
Summary
Converging evidence suggests that patients with bipolar disorder suffer from deficits in
neurocognitive functioning that persist, despite remission of acute affective symptoms. These
impairments contribute directly to functional disability, highlighting the need for
interventions above and beyond standard treatments in order to achieve a full inter-episode
recovery. The current study aims to investigate the safety and efficacy of a dopamine agonist
(pramipexole), on these persistent cognitive abnormalities in euthymic bipolar patients using
a placebo-controlled, adjunctive, 12-week trial design.
Phase:
Phase 4
Details
Lead Sponsor:
Brigham and Women's Hospital Icahn School of Medicine at Mount Sinai
Collaborators:
Icahn School of Medicine at Mount Sinai National Institute of Mental Health (NIMH) Northwell Health The Zucker Hillside Hospital